FDA
-
-
-
-
-
-
-
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
-
-
-
-
-
-
-
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
-
-
-
-
-
-
-
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
-
-
-
-
-
-
-
Actinium Pharmaceuticals, Inc. to Present Two Abstracts at the 2026 AACR Annual Meeting
-
-
-
-
-
-
-
ACTINIUM reports lung cancer drug data at medical conference
-
-
-
-
-
-
-
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvic
-
-
-
-
-
-
-
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
-
334,272 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


